| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PLoSO..1023581S |
| P356 | DOI | 10.1371/JOURNAL.PONE.0123581 |
| P932 | PMC publication ID | 4430315 |
| P698 | PubMed publication ID | 25970626 |
| P5875 | ResearchGate publication ID | 276361621 |
| P50 | author | Richard Neubig | Q67330747 |
| Benita Sjögren | Q79300299 | ||
| P2093 | author name string | Steven Swaney | |
| P2860 | cites work | Diversity in tissue expression, substrate binding, and SCF complex formation for a lectin family of ubiquitin ligases | Q24306888 |
| The cullin 4B-based UV-damaged DNA-binding protein ligase binds to UV-damaged chromatin and ubiquitinates histone H2A | Q24309117 | ||
| WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase | Q24316117 | ||
| A gene atlas of the mouse and human protein-encoding transcriptomes | Q24568043 | ||
| Understanding Molecular Recognition by G protein βγ Subunits on the Path to Pharmacological Targeting | Q24635233 | ||
| Diversity of degradation signals in the ubiquitin-proteasome system | Q24642979 | ||
| Deregulation of RGS2 in cardiovascular diseases | Q24654920 | ||
| Skp1 stabilizes the conformation of F-box proteins | Q54585205 | ||
| Profile of RGS expression in single rat atrial myocytes | Q77368792 | ||
| Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells | Q82437098 | ||
| The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation. | Q36436025 | ||
| Ubiquitin and ubiquitin-like proteins in cancer pathogenesis | Q36601000 | ||
| Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer | Q36627994 | ||
| The bitter end: the ubiquitin-proteasome system and cardiac dysfunction | Q36764396 | ||
| A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. | Q37432745 | ||
| CRL4s: the CUL4-RING E3 ubiquitin ligases | Q37440298 | ||
| Regulator of G-protein signaling (RGS) proteins in cancer biology | Q37533157 | ||
| Regulators of G protein signaling proteins as targets for drug discovery. | Q37778514 | ||
| The cullin protein family | Q37873586 | ||
| RGS2 suppresses breast cancer cell growth via a MCPIP1-dependent pathway. | Q38960056 | ||
| Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation | Q39237066 | ||
| Small Molecule Inhibitors of Regulator of G Protein Signalling (RGS) Proteins | Q41470342 | ||
| RGS4 is arginylated and degraded by the N-end rule pathway in vitro | Q41732590 | ||
| Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. | Q42722283 | ||
| Regulation of RGS proteins by chronic morphine in rat locus coeruleus | Q44373732 | ||
| Altered expression of regulators of G-protein signaling (RGS) mRNAs in the striatum of rats undergoing dopamine depletion | Q44593845 | ||
| Association of RGS2 variants with panic disorder in a Japanese population | Q44964445 | ||
| X-linked intellectual disability gene CUL4B targets Jab1/CSN5 for degradation and regulates bone morphogenetic protein signaling | Q46184056 | ||
| Are RGS2 gene polymorphisms associated with high blood pressure in an ethnicity- and gender-specific manner? | Q46214466 | ||
| Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy | Q46870087 | ||
| Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development | Q27643965 | ||
| Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development | Q27685122 | ||
| Mechanisms underlying ubiquitination | Q27860656 | ||
| The ubiquitin system | Q27860803 | ||
| A new subfamily of structurally related human F-box proteins | Q28207823 | ||
| N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells | Q28283150 | ||
| F-box proteins: the key to protein degradation | Q28296039 | ||
| Cellular regulation of RGS proteins: modulators and integrators of G protein signaling | Q28646133 | ||
| The druggable genome | Q29547361 | ||
| SCF and Cullin/Ring H2-based ubiquitin ligases | Q29547637 | ||
| Ablation of arginylation in the mouse N-end rule pathway: loss of fat, higher metabolic rate, damaged spermatogenesis, and neurological perturbations | Q30886015 | ||
| Proteasome inhibitors: a novel class of potent and effective antitumor agents. | Q33864458 | ||
| Regulation of T cell activation, anxiety, and male aggression by RGS2. | Q33920958 | ||
| RGS4 and RGS5 are in vivo substrates of the N-end rule pathway | Q34085136 | ||
| RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy | Q34108087 | ||
| Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins | Q34128004 | ||
| Regulators of G-protein signalling as new central nervous system drug targets. | Q34139169 | ||
| Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure. | Q34144328 | ||
| Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice | Q34177503 | ||
| Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study | Q34218218 | ||
| Thinking outside of the "RGS box": new approaches to therapeutic targeting of regulators of G protein signaling. | Q34310119 | ||
| Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage | Q34353149 | ||
| Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population | Q34432231 | ||
| Ubiquitin-mediated degradation of cellular proteins in health and disease | Q34490180 | ||
| Structural assembly of cullin-RING ubiquitin ligase complexes | Q34762436 | ||
| A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins | Q34960765 | ||
| Evidence for enhanced M3 muscarinic receptor function and sensitivity to atrial arrhythmia in the RGS2-deficient mouse | Q35016294 | ||
| Alternative ubiquitin activation/conjugation cascades interact with N-end rule ubiquitin ligases to control degradation of RGS proteins. | Q35151521 | ||
| Regulators of G protein signalling: potential targets for treatment of allergic inflammatory diseases such as asthma | Q35186648 | ||
| Cullin 4B protein ubiquitin ligase targets peroxiredoxin III for degradation | Q35213523 | ||
| The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended | Q35633109 | ||
| The development of proteasome inhibitors as anticancer drugs | Q35773857 | ||
| Regulators of G protein signaling: potential drug targets for controlling cardiovascular and immune function | Q35793755 | ||
| Cardiotonic steroids stabilize regulator of G protein signaling 2 protein levels | Q36174768 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | proteasomal protein catabolic process | Q14905468 |
| F-box protein 44 | Q21100961 | ||
| Damage specific DNA binding protein 1 | Q21108214 | ||
| Cullin 4B | Q21112921 | ||
| Arginyltransferase 1 | Q21116740 | ||
| F-box protein 44 | Q21495700 | ||
| Arginyltransferase 1 | Q21496108 | ||
| Damage specific DNA binding protein 1 | Q21497447 | ||
| Regulator of G-protein signaling 2 | Q21980128 | ||
| Cullin 4B | Q21981694 | ||
| P304 | page(s) | e0123581 | |
| P577 | publication date | 2015-05-13 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex | |
| P478 | volume | 10 |
| Q30278581 | Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis |
| Q36852562 | Digoxin-Mediated Upregulation of RGS2 Protein Protects against Cardiac Injury. |
| Q57149243 | G Protein-Coupled Receptor Systems as Crucial Regulators of DNA Damage Response Processes |
| Q47703780 | Proteolytic degradation of regulator of G protein signaling 2 facilitates temporal regulation of Gq/11 signaling and vascular contraction |
| Q47637709 | Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins |
| Q30397640 | The evolution of regulators of G protein signalling proteins as drug targets - 20 years in the making: IUPHAR Review 21. |
Search more.